Backers included California Technology Ventures (CTV), a Southern California-based venture capital firm that focuses its investments in the fields of Life Sciences and Information Technology. In conjunction with the funding, CTV Managing Director Alex Suh will join the AiVita Board of Directors.
California Technology Ventures also holds the right to invest additional funds at a future date.
The company intends to use the funds for general operations and for the further development of the its pipeline of programs.
Led by Dr. Hans Keirstead, CEO, AiVita Biomedical is advancing commercial and clinical-stage programs utilizing curative and regenerative medicines. Its active programs currently include a stem cell-based skin care product to address several key signs of aging, and a novel cancer immunotherapy applicable to multiple solid tumor types.
The company anticipates a Phase II clinical trial exploring the efficacy of its immunotherapeutic approach in patients with ovarian cancer within the year.
FinSMEs
11/06/2016